The consensus view remains that if China can get a grip on what...
Category:
Health
Latest
Loss of smell most prevalent symptom of long Covid : Study
''We found that fatigue was the most common symptom, whilst...
Health minister reviews Covid situation, directs officials to be alert, strengthen surveillance
''In view of the rising cases of Covid19 in some countries,...
No coronavirus patient under home isolation in Delhi has died in July: study
“During the June 24 to July 8 fortnight, a total of 691 deaths took place in Delhi, which is an average of 46 deaths per day during this period,” the government said in a statement.
According to the study, the number of daily deaths in past few days has come down. From a high of 101 daily deaths in mid-June, daily deaths have come down to around 46 deaths during the last fortnight, registering a significant improvement, it said.
Healthcare spends, making India slum-free should be govt’s priority: Experts
“To change this crisis to an opportunity, let us invest in the health sector,” SBI’s chief economist S K Ghosh said, suggesting a plan to build a 500-bed hospital in 250 districts at a cost of Rs 60,000 crore over the next two years
Covid-19 left 147 mn unemployed, global consumption loss at $3.8 trn: Study
“Our study highlights the interconnected nature of international supply chains, with observable global spillover effects across a range of industry sectors, such as manufacturing, tourism and transport,” said study researcher Arunima Malik from the University of Sydney in Australia.
Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed
Findings from the analysis showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.
Relying on market forces for Covid-19 drugs would prolong the deadly pandemic:Bill Gates
With hundreds of vaccine projects under way and governments in Europe and the United States investing billions of dollars in research, trials and manufacturing, there is concern that richer nations could scoop up promising medicines against the new coronavirus, leaving developing countries empty-handed.
The European Commission and the World Health Organization have warned of an unhealthy competition in the scramble for a medicine seen as key to saving lives and resolving economic chaos sowed by virus, while some officials in Washington have indicated they would seek to prioritize U.S residents.
Biocon secures approval to use drug on coronavirus patients
“The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered,” said Kiran Mazumdar-Shaw, the firm’s executive chairperson.
The control group which did not receive Itolizumab unfortunately suffered deaths, she said, adding that the “first-in-class” drug will save lives and help reduce the mortality rate in India.
Pandemic-proofing: Insurance may never be the same again
Marsh, the world’s biggest insurance broker, has teamed up with AXA XL, part of France’s AXA,and data firm Arity, which is part of Allstate, to help businesses such as U.S. supermarket chains, restaurants and e-commerce retailers cope with the challenges of social distancing.
Tech firm Machine Cover, for example, aims to offer policies next year that would give relief during lockdowns. Using apps and other data sources, the Boston-based company measures traffic levels around businesses such as restaurants, department stores, hairdressers and car dealers
General and health insurers launch mandatory Corona covers,Bajaj Allianz General’s prm ranges between Rs447 to Rs 5,630 for a Rs 50k policy
The ‘Corona Kavach’ policy indemnifies policyholders for medical expenses on hospitalization for the treatment of the virus and includes the expense incurred on treating co-morbidity along with COVID-19. The policy will also cover road ambulance expenses, in case the service is opted for the purpose of hospitalization due to COVID-19. Home Care Expenses benefit (upto a period of 14 days) will also be covered in the policy for those seeking treatment within the comfort of their own homes, on the advice of a medical practitioner,said HDFC Ergo General Insurance.
Record single-day jump of 26,506 COVID-19 cases in India
Why reveal names of COVID-19 patients? it involves privacy: Bombay HC
The PIL said when the fundamental right to life and right to lead a healthy life clash with the fundamental right to privacy, then the court needs to see which of these rights would advance public morality and interest.